Home/Filings/4/0000914190-19-000460
4//SEC Filing

WIENS HAROLD J 4

Accession 0000914190-19-000460

CIK 0000842023other

Filed

Dec 5, 7:00 PM ET

Accepted

Dec 6, 4:50 PM ET

Size

23.1 KB

Accession

0000914190-19-000460

Insider Transaction Report

Form 4
Period: 2019-12-04
Transactions
  • Sale

    Common Stock

    2019-12-04$216.47/sh485$104,9906,736 total
  • Sale

    Common Stock

    2019-12-04$219.31/sh80$17,5455,221 total
  • Exercise/Conversion

    Common Stock

    2019-12-04$87.83/sh+2,000$175,6607,221 total
  • Sale

    Common Stock

    2019-12-04$217.29/sh514$111,6856,222 total
  • Sale

    Common Stock

    2019-12-04$218.75/sh921$201,4735,301 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2019-12-042,0000 total
    Exercise: $87.83From: 2014-05-15Exp: 2024-05-15Common Stock (2,000 underlying)
Holdings
  • Stock Option (right to buy)

    Exercise: $87.34From: 2016-10-29Exp: 2025-10-28Common Stock (4,260 underlying)
    4,260
  • Stock Option (right to buy)

    Exercise: $125.05From: 2018-10-25Exp: 2027-10-26Common Stock (3,125 underlying)
    3,125
  • Stock Option (right to buy)

    Exercise: $179.84From: 2019-10-24Exp: 2028-10-25Common Stock (1,898 underlying)
    1,898
  • Stock Option (right to buy)

    Exercise: $101.19From: 2017-10-26Exp: 2026-10-26Common Stock (3,985 underlying)
    3,985
  • Stock Option (right to buy)

    Exercise: $201.64Exp: 2029-10-24Common Stock (2,011 underlying)
    2,011
  • Stock Option (right to buy)

    Exercise: $91.78From: 2014-10-30Exp: 2024-10-30Common Stock (4,000 underlying)
    4,000
Footnotes (6)
  • [F1]The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2019.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.21 to $217.54, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.28 to $218.96, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.31 to $219.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

BIO-TECHNE Corp

CIK 0000842023

Entity typeother

Related Parties

1
  • filerCIK 0001197788

Filing Metadata

Form type
4
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 4:50 PM ET
Size
23.1 KB